MEDICINOVA INC. - COMMON STOCK

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

14 4 2025 19:00:00 提供 Nasdaq GlobeNewswire

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

08 4 2025 19:00:00 提供 Nasdaq GlobeNewswire

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

05 12 2024 18:00:00 提供 Nasdaq GlobeNewswire

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

19 11 2024 09:00:00 提供 Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

14 11 2024 18:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: MEDICINOVA INC. - COMMON STOCK

12 11 2024 13:48:52 提供 NetDania Notify

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

11 11 2024 18:00:00 提供 Nasdaq GlobeNewswire

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

23 10 2024 19:00:00 提供 Nasdaq GlobeNewswire

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

30 9 2024 09:00:00 提供 Nasdaq GlobeNewswire

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

09 9 2024 19:00:00 提供 Nasdaq GlobeNewswire

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

03 9 2024 19:00:00 提供 Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

29 8 2024 19:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

12 8 2024 11:21:20 提供 NetDania Notify

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

07 8 2024 15:10:41 提供 NetDania Notify

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

06 8 2024 10:25:17 提供 NetDania Notify

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

05 8 2024 09:46:33 提供 NetDania Notify

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

20 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

05 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

03 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

28 5 2024 06:00:00 提供 Nasdaq GlobeNewswire